Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use.

Blood - 11 Oct 2018

Brennan Margs S, Chang Catherine, Tai Lin, Lessene Guillaume, Strasser Andreas, Dewson Grant, Kelly Gemma L, Herold Marco J

Abstract excerpt

Myeloid cell leukemia-1 (MCL-1) is a prosurvival B-cell lymphoma 2 (BCL-2) family member required for the sustained growth of many cancers. Recently, a highly specific MCL-1 inhibitor, S63845, showing sixfold higher affinity to human compared with mouse MCL-1, has been described. To accurately test efficacy and tolerability of this BH3-mimetic (BH3-only protein mimetic) drug in preclinical cancer models, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Evaluation, Preclinical

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Screening Assays, Antitumor

Share to Lymphoma

Share to Mice, Inbred BALB C

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Pyrimidines

Share to Thiophenes

Source

Identifiers

PMID: 30139826
DOI: 10.1182/blood-2018-06-859405

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use.PMID 30139826Read ↗

Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53.Semantic proximity Read ↗

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established TherapiesSemantic proximity Read ↗

Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemiaSemantic proximity Read ↗

Mouse models of human AML accurately predict chemotherapy response.Semantic proximity Read ↗

Mcl‐1 targeting could be an intriguing perspective to cure cancerSemantic proximity Read ↗

Last but not least: BFL-1 as an emerging target for anti-cancer therapiesSemantic proximity Read ↗

A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.Semantic proximity Read ↗

Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1Semantic proximity Read ↗

BH3 Mimetics in Hematologic MalignanciesSemantic proximity Read ↗

Toward Targeting Antiapoptotic MCL-1 for Cancer TherapySemantic proximity Read ↗

New murine models of aggressive lymphoma.Semantic proximity Read ↗

Development of ZMYM2-FGFR1 driven AML in human CD34+ cells in immunocompromised mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.